Lercanidipine hydrochloride cas: 132866-11-6

CAS NO: 132866-11-6
Chemical Name: Lercanidipine Hydrochloride
Molecular Formula: C_36H_41N_3O_6·HCl
Formula Weight: 648.2 g/mol
CAS Number: 132866-11-6
Description Review
Description


Overview of Lercanidipine Hydrochloride: A well-known pharmaceutical ingredient, lercanidipine hydrochloride is essential to several contemporary treatments. The medical community has shown significant interest in its effectiveness and safety profile.

Advantages of Lercanidipine hydrochloride, comparison to other calcium channel blockers, Lercanidipine hydrochloride dosage are search engine keywords associated with Lercanidipine hydrochloride.
The way that lercanidipine hydrochloride works,
Adverse reactions associated with Lercanidipine hydrochloride,

Among other calcium channel blockers, lercanidipine hydrochloride competes with Amlodipine, Nifedipine, and Felodipine. However, lercanidipine hydrochloride has certain distinct pharmacokinetic features that could make it the better choice in some clinical situations.
Benefits to Health:
The primary reason for the use of this substance is due to its ability to lower blood pressure. Effectively lowering blood pressure reduces stroke, heart attack, and kidney disease risk.

Possible Effects:
In addition to its antihypertensive qualities, lercanidipine hydrochloride may have positive effects on endothelial function and arterial stiffness, which might enhance its cardiovascular preventive benefits.

Lercanidipine works by decreasing calcium ion influx via L-type calcium channels in vascular smooth muscle cells. Vasodilation ensues as a consequence of this action, resulting in reduced peripheral resistance and pressure.

Safety Profile:
Most people can handle lercanidipine hydrochloride without any problems. When used as directed, it has a low incidence of side effects and a safety profile similar to other calcium channel blockers.

Effects:
Common side effects include dizziness, headache, flushing, and peripheral edema. Usually, they are minor and fleeting.

dosage Information:
The normal dosage regimen for Lercanidipine hydrochloride is a once-daily oral consumption of 10mg. Patient-specific responses and the presence of concurrent medical conditions may require dosage modifications.

Contraindications:
Lercanidipine hydrochloride interacts adversely with specific medications, including CYP3A4 inhibitors, and should not be administered to patients with a documented hypersensitivity reaction, severe hepatic impairment, or known hypersensitivity to the drug.

Conclusion:
Lercanidipine hydrochloride is a strong and effective way to treat high blood pressure. Effective blood pressure management with an appropriate safety margin is guaranteed by its pharmacological profile, making it a useful tool in cardiovascular therapy.

Lercanidipine hydrochloride cas: 132866-11-6

People Also Ask
Is Lercanidipine suitable for long-term use?
It is thought that lercanidipine is safe to use for the long term to treat hypertension as long as proper medical supervision and dose instructions are followed.


Can Lercanidipine be used in people with renal disease?
Patients who are under meticulous medical supervision and have mild to moderate kidney disease may be prescribed Lercanidipine. In cases of serious kidney failure, however, it should not be used anymore.


What is the difference between Lercanidipine and Amlodipine?
In the treatment of hypertension, both lercanidipine and amlodipine are useful medications. Patients generally choose Lercanidipine because to its decreased edema risk.


When using lercanidipine, are there any food restrictions?
While using Lercanidipine, it is best to avoid grapefruit and grapefruit juice since they might interfere with the drug's metabolism, resulting in higher blood concentrations.



  • Lercanidipine mechanism of action,
  • Lercanidipine for hypertension,
  • Lercanidipine vs amlodipine,
  • Lercanidipine side effects,
  • Lercanidipine dosage,
  • Lercanidipine pharmacokinetics,
  • Lercanidipine interactions,
  • Lercanidipine and grapefruit juice,
  • Lercanidipine liver metabolism,
  • Lercanidipine long-term efficacy,
  • Lercanidipine regulatory status,
  • Lercanidipine blood pressure management.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code